Overview

Lamotrigine in Treatment Resistant Depression in Adolescents

Status:
Terminated
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of this study is that in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft). Our Primary Aim is to determine the efficacy and safety of Lamotrigine-augmentation of fluoxetine for treatment-resistant depression in adolescents. Our Secondary Aims are to characterize the factors associated with treatment-resistance for adolescents with major depression. Also to assess the relationships in the families of adolescents with major depression as they enter treatment, and to track the differences in family relationships for adolescents who respond or do not respond. We postulate that tense, frustrated, irritable, and over-involved relationships constitute a risk factor for attenuated improvement or relapse.
Phase:
N/A
Details
Lead Sponsor:
Maine Medical Center
MaineHealth
Collaborator:
GlaxoSmithKline
Treatments:
Anticonvulsants
Fluoxetine
Lamotrigine
Sertraline